Home Cart Sign in  
Chemical Structure| 418805-02-4 Chemical Structure| 418805-02-4

Structure of PYR-41
CAS No.: 418805-02-4

Chemical Structure| 418805-02-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

PYR-41 is a selective E1 enzyme inhibitor that can inhibit the ubiquitination process with an IC50 value of 10 μM. PYR-41 has anticancer and antiviral effects and can be used in research on protein degradation and cell signaling.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of PYR-41

CAS No. :418805-02-4
Formula : C17H13N3O7
M.W : 371.30
SMILES Code : O=C(OCC)C1=CC=C(N2NC(/C(C2=O)=C/C3=CC=C([N+]([O-])=O)O3)=O)C=C1
MDL No. :MFCD01469983
InChI Key :ARGIPZKQJGFSGQ-LCYFTJDESA-N
Pubchem ID :5335621

Safety of PYR-41

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H317
Precautionary Statements:P280

Isoform Comparison

Biological Activity

Target
  • E1 Activating

    Ubiquitin-activating Enzyme E1, IC50:<10 μM

In Vitro:

Cell Line
Concentration Treated Time Description References
oocytes 50 μM 6 hours PYR-41 significantly increased TAp63 α accumulation, suggesting that TAp63 α undergoes rapid turnover through ubiquitin-dependent proteasomal degradation. PMC11544165
A431 cells 100 μM 30 minutes Inhibition of ubiquitin E1 activating enzyme, reducing PD-L1 mono- and multiubiquitination, and blocking EGF-stimulated increases in PD-L1 protein levels PMC5358937
Bone marrow-derived dendritic cells (BMDCs) 1 µM or 5 µM 30 min pretreatment, followed by co-incubation with Ang II for 24 hr PYR41 significantly inhibited Ang II-induced phenotypic maturation of BMDCs, reducing the expression of CD40 and CD80. PMC4008238
DC2.4 cells 1 µM or 5 µM 30 min pretreatment, followed by co-incubation with Ang II for 15 min or 30 min PYR41 significantly inhibited Ang II-induced activation of NF-κB and ERK/STAT1 signaling pathways. PMC4008238
HeLa cells 20 µM 15 minutes PYR-41 treatment rapidly induced the accumulation of dynein at spindle poles, suggesting that dynein localization may be regulated by ubiquitination. PMC6170511

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
mice FeCl3-induced carotid artery thrombosis model intravenous injection 5 mg/kg Twice a week for 21 days PYR41 significantly prolonged the time to occlusion to 26 min, indicating that deubiquitinase inhibition reduced thrombosis. PMC4662625

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.47mL

2.69mL

1.35mL

26.93mL

5.39mL

2.69mL

References

 

Historical Records

Categories